BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22560618)

  • 1. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways: targeting hsp90--who benefits and who does not.
    Scaltriti M; Dawood S; Cortes J
    Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
    Lee CH; Hong HM; Chang YY; Chang WW
    Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J; Whitesell L
    Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
    Hanson BE; Vesole DH
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
    Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
    Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS; Kerr TD
    Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitors in breast cancer: a systematic review.
    Zagouri F; Sergentanis TN; Chrysikos D; Papadimitriou CA; Dimopoulos MA; Psaltopoulou T
    Breast; 2013 Oct; 22(5):569-78. PubMed ID: 23870456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of HSP90 client proteins in human breast cancer.
    Shipp C; Watson K; Jones GL
    Anticancer Res; 2011 Jun; 31(6):2095-101. PubMed ID: 21737627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.